ESMO Sarcoma and Rare Cancers 2023 | Which patients with pancreatic cancer will benefit from local intervention?

Dirk Arnold, MD, PhD, Asklepios Tumorzentrum Hamburg AK Altona, Hamburg, Germany, outlines the importance of stratifying patients with pancreatic cancer according to disease prognosis and explains why this categorisation should influence the decision to intervene either locally or systemically. Prof. Arnold continues by proposing patients with better prognosis should receive local intervention such as surgery while tumors with a more complex disease progression should be defined on the basis of molecular and pathological characteristics. This interview took place at the 2023 ESMO annual Sarcoma and Rare Cancers congress in Lugano, Switzerland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.